What Is a PCCP? How FDA Lets AI Devices Change Without a New Submission
Your data science team has a retrained model ready. The software flags lesions in endoscopy images, and the new version was trained on images from additional clinical sites. It does better on every metric you track. The question from your CEO is short: when can we ship it?
Without a plan, the honest answer starts with "it depends" and often ends with a new 510(k). With a Predetermined Change Control Plan (PCCP) authorized alongside the device, the answer can be different: if the update stays inside the plan FDA already reviewed, you implement it without a new marketing submission. The review happened up front, on the scope of the change and the method for verifying it.
That is the whole idea of a PCCP. The details decide whether your update is actually inside the plan.
Why did FDA create the PCCP?
AI-enabled device software is built to improve. Retrain a model on more data and the same product performs differently. Under the conventional rules, a change that could significantly affect safety or effectiveness means a new 510(k). For a PMA device, it means a PMA supplement.
Submitting for every update slows improvement down. Letting devices change without review is not an option either. The PCCP resolves this by moving the review earlier: FDA reviews what you plan to change and how you will verify it, and you are then held to that plan.
The statutory basis is section 515C of the Federal Food, Drug, and Cosmetic Act (FD&C Act), added by the Food and Drug Omnibus Reform Act of 2022 (FDORA). Section 515C applies to devices generally, not only to AI. For AI, FDA's final guidance "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions," from FDA's Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER), sets out what a PCCP should contain. It was first issued on December 4, 2024; the current version is dated August 18, 2025. As the title says, the guidance covers AI-enabled device software functions.
What goes into a PCCP?
A PCCP is not a separate procedure. It is a section of the marketing submission, reviewed with the rest of it. The guidance describes three components: the Description of Modifications, the Modification Protocol and the Impact Assessment.
| Component | What it answers | What it typically covers |
|---|---|---|
| Description of Modifications | Which changes, and how far? | The specific modifications planned and their boundaries |
| Modification Protocol | How will each change be verified and implemented? | Data management, retraining, performance evaluation, update methods |
| Impact Assessment | What could the changes do to safety and effectiveness? | Benefits and risks of the changes, and how risks are addressed |
The three parts lean on each other. A modification with no matching protocol has no agreed way to show it works. A protocol with no impact assessment gives no reason why its checks are enough.
Which submissions can carry a PCCP?
A PCCP can be included in a 510(k), a De Novo request or a PMA (including a PMA supplement). It is authorized together with the device: approved with a PMA, granted with a De Novo, cleared with a 510(k).
The plan is part of that authorization. Changing the plan itself, or adding one to a device already on the market, calls for a new marketing submission.
What counts as "within the plan"?
A change is within the plan when three things hold together. It is one of the modifications in the Description of Modifications. It is verified and implemented as the Modification Protocol says. And it meets the protocol's own criteria for success. One out of three is not enough.
When a change falls outside the plan, the PCCP no longer covers it. You are back to FDA's usual rules for deciding whether a change needs a new submission: a new 510(k), a PMA supplement, or, if no submission is required, documentation in your quality system.
Back to the retrained model. If "retraining with data from additional sites" is a listed modification, the protocol was followed, and the results met its criteria, it ships under the plan. If the team also widened the patient population or changed what the output tells the clinician, that part is a separate question.
After the change: did you follow the plan?
In our view, the PCCP shifts the question asked after authorization. It is less "did performance improve?" and more "was the change made by the agreed method, did it meet the acceptance criteria, and does the device remain safe and effective?" Three practical points follow.
- Plan early. Data additions, re-evaluation and the update method are easier to write into a plan when they are part of the development design from the start. A PCCP can be added to a device already on the market, but that takes a new marketing submission
- Keep the scope narrow. The wider the planned changes, the more the reviewer will ask. We think performance updates that leave the Indications for Use untouched are the realistic starting point
- Write the protocol so the outcome is predictable. A reviewer should be able to read the test methods and acceptance criteria and know in advance what a passing update looks like
We also think a PCCP is a design document as much as a regulatory one. Teams that cannot yet describe how they would verify a retrained model are, in our view, not ready to ask FDA to pre-authorize one.
How to read PCCP language in public records
FDA publishes a 510(k) Summary for cleared devices, a Decision Summary and Classification Order for granted De Novo requests, and a Summary of Safety and Effectiveness Data (SSED) for approved PMAs. When a device has an authorized PCCP, these documents may say so, sometimes with a short description of the planned changes.
When you find PCCP language, read it for three things:
- Which modifications are listed. Retraining, threshold updates, new input sources: the named types tell you what the applicant planned for
- What is held fixed. Statements that the Indications for Use or intended population will not change mark the edge of the plan
- How verification is described. References to test datasets, performance metrics and acceptance criteria show how seriously the protocol was written up
Read with care. A summary is not the full submission. In describing its AI-enabled device list, FDA notes that summaries "are not all inclusive and do not include most of the information that may be submitted in an application." In our view, that cuts both ways: a short PCCP mention says little about the plan's real scope, and the absence of one in a summary does not prove that no plan exists.
One note on this site. Search offers a PCCP filter. As of October 9, 2026, we have checked PCCP status for all 2026 decisions, about 36 percent of 2025 decisions and about 5 percent of 2023–2024 decisions, so counts for years before 2026 cover only the records checked so far. This article names no individual devices.
Find, star and compare PCCP language on RA Craft Database
- Open Search and tick the AI/ML filter, the PCCP filter, or both. Treat the PCCP flag for decisions before 2026 as a starting point, since not all of those records have been checked
- Narrow by Product Code to your device type. Keywords is keyword search across device name, applicant, Indications for Use and device description, so short terms work better than sentences
- Star (☆) the records worth a closer read. They are saved to My Workspace
- In My Workspace, tick "Compare" on a few records, press "N selected for comparison", and open the comparison table
The comparison table is source material extracted from FDA's public documents, not a substantial equivalence table. Read the Software sections side by side to see how other applicants describe changes and verification, then open the FDA documents linked from each record before you draft your own plan.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles